Can Erbitux Make Inroads In First-line Colon Cancer With Approved Companion Dx In Tow?
This article was originally published in The Pink Sheet Daily
Erbitux wins FDA approval for first-line metastatic colorectal cancer negative for KRAS mutations detected with a companion diagnostic specifically approved for the drug. In theory, earlier use could help shore up sales. But the drug faces a tough competitor in the dominant Avastin and new products are on the near horizon.
You may also be interested in...
A pending regulatory decision in the U.S. and Europe for oncology drug RA 223 and improving sales of AMD drug Eylea, both brought in through partnership activity, may bring some calm to the recently stormy seas traveled by Bayer Healthcare.
Ahead of schedule, FDA approves Stivarga (regorafenib), partnered with Onyx, for late-stage mCRC patients with few options left. Bayer prices drug at under $10,000 a month, on par with competing treatments.
A Center for Devices and Radiological Health representative tells a conference on drug/diagnostic co-development that it doesn’t matter how well designed a study for a therapeutic agent is if the accompanying biomarker-targeted test is not reliable and uniformly implemented.